{"id":"NCT02089347","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old","officialTitle":"Immunogenicity and Safety of the Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (SP306) Given Intramuscularly Compared to Diphtheria and Tetanus Toxoids Adsorbed (DT) Given Subcutaneously in Japanese Adolescents 11 - 12 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2014-09","completion":"2015-03","firstPosted":"2014-03-17","resultsPosted":"2015-10-08","lastUpdate":"2017-05-30"},"enrollment":534,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Tetanus","Diphtheria","Pertussis"],"interventions":[{"type":"BIOLOGICAL","name":"Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed","otherNames":["Adacel","SP306 (in Japan)"]},{"type":"BIOLOGICAL","name":"Diphtheria and Tetanus toxoids adsorbed","otherNames":["DT vaccine"]}],"arms":[{"label":"SP306 Group","type":"EXPERIMENTAL"},{"label":"DT Group","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the study is to generate additional safety and immunogenicity data to support the registration of the product in Japan.\n\nPrimary objectives:\n\n* To demonstrate the non-inferiority of SP306 versus DT (DT 0.1mL) vaccine in terms of diphtheria and tetanus booster response rate (proportion of subjects with booster responses) and seroprotection rate (percentage of subjects with antitoxin concentrations â‰¥0.1 IU/mL) at 28 days (window 28-35 days) after one injection in Japanese adolescents 11-12 years of age.\n* To evaluate the immune response of SP306 against the pertussis antigens PT and FHA in terms of booster response rate (proportion of subjects with booster responses) at 28 days (window 28-35 days) after one injection in Japanese adolescents 11-12 years of age.\n\nSecondary objectives:\n\n* To further evaluate the immune response of the study vaccines against diphtheria, tetanus and pertussis antigens.\n* To assess the safety of the study vaccines after one injection in Japanese adolescents 11-12 years of age.","primaryOutcome":{"measure":"Percentage of Participants With Diphtheria and Tetanus Post-vaccination Booster Response Following Vaccination With Either SP306 or DT","timeFrame":"Day 28 post-vaccination","effectByArm":[{"arm":"SP306 Group","deltaMin":99.7,"sd":null},{"arm":"DT Group","deltaMin":98.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":24},"locations":{"siteCount":19,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":356},"commonTop":["Nasopharyngitis","Injection site Pruritus"]}}